Boostrix GlaxoSmithKline Biologicals - Treatment for Prevention of Diphtheria, Tetanus & Pertussis in Adolescents
Boostrix is indicated as a single dose active booster immunization against tetanus, diphtheria, and pertussis in individuals 10 through 18 years of age, thereby adding a pertussis component to the routine tetanus/diphtheria booster currently administered to teens.Posted: May 2005
Related Articles:
- FDA approves Boostrix to prevent tetanus, diphtheria, and pertussis in older people - July 11, 2011
- FDA Approves GlaxoSmithKline Tetanus, Diphtheria, Whooping Cough Vaccine, Boostrix, for Adults - December 13, 2008
- GlaxoSmithKline Receives Unanimous Favorable Recommendation by FDA Advisory Committee for Boostrix - March 15, 2005
- GlaxoSmithKline Submits Biologics License Application for FDA Approval of Boostrix - July 7, 2004
Boostrix (tetanus, diphtheria, acellular pertussis vaccine (Tdap)) FDA Approval History
